Tirzepatide (Mounjaro, Zepbound) and Black patients
Brand names: Mounjaro, Zepbound
What Tirzepatide does
Tirzepatide is the first dual GLP-1/GIP receptor agonist approved in the US — it activates two gut-hormone pathways at once. For type-2 diabetes (Mounjaro) and obesity (Zepbound), it has produced the largest A1C reductions and weight losses of any currently marketed drug, with once-weekly injection.
What the evidence says for Black patients
SURPASS-2 (Frías et al., NEJM 2021;385:503–15, PMID 34170647) and SURMOUNT-1 (Jastreboff et al., NEJM 2022;387:205–16, PMID 35658024) established tirzepatide's glycemic and weight-loss efficacy. Subgroup analyses by race show consistent A1C reduction across Black, Hispanic, and white participants, though absolute weight loss in Black participants averaged roughly 1–2 kg less at the highest dose — a pattern seen with other GLP-1s and attributed to small differences in body composition response rather than drug efficacy.
SURMOUNT-OSA (Malhotra et al., NEJM 2024;391:1193–1205, PMID 38912654) showed tirzepatide reduces apnea-hypopnea index by half in obese adults with obstructive sleep apnea — relevant because Black adults have higher rates of undiagnosed OSA.
As with semaglutide, prescribing disparity is a major equity issue. 2024 commercial-pharmacy claims data show disproportionately low prescribing to Black adults with qualifying clinical profiles. Cost (roughly $1,000–$1,300 monthly list price) and persistent 2023–2024 supply constraints have kept access unequal.
Common alternatives
Semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda) are GLP-1 monotherapies with established cardiovascular-outcome data. For type-2 diabetes without obesity, SGLT2 inhibitors (empagliflozin, dapagliflozin) are equally reasonable first-line choices.
Side effects
- Nausea, vomiting, diarrhea, constipation — most common; dose-titration reduces
- Injection-site reactions
- Pancreatitis (rare)
- Gallbladder disease (cholelithiasis)
- Boxed warning: thyroid C-cell tumors in rodents; contraindicated with personal/family history of medullary thyroid cancer or MEN2
- Rare diabetic retinopathy progression
Factors that affect adherence
GI tolerability improves markedly with slow dose escalation (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg). Cost is the dominant barrier; manufacturer savings cards, patient-assistance programs, and insurance PA processes consume clinician and patient time. Zepbound Medicare Part D coverage expanded in 2024 for cardiovascular-risk reduction in obesity without diabetes.
Questions to ask your doctor
Bring this list to your next appointment.
- Will my insurance cover Mounjaro (diabetes) or Zepbound (obesity) for my situation?
- If I can't get tirzepatide, is semaglutide a reasonable substitute?
- What dose-escalation schedule will we follow if I have nausea?
- Should I have a baseline eye exam if I have retinopathy?
References
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). NEJM. 2021;385:503–515. PMID 34170647.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM. 2022;387:205–216. PMID 35658024.
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). NEJM. 2024;391:1193–1205. PMID 38912654.
- U.S. Food and Drug Administration. Mounjaro (tirzepatide) label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
Medical disclaimer
This page is patient education, not prescribing guidance. It summarizes the published evidence about how this medication has been studied in Black patients — it is not a substitute for the judgment of your personal clinician. Never start, stop, or change a prescription based on something you read here. If you have questions about your medication, call your prescriber or pharmacist. For emergencies, call 911.
Read our editorial standards for how we source, review, and update these pages.